
    
      This is a randomized, double blind clinical trial testing intervention by standardized GMT.
      The study cohort will include 10 SSc patients with GI symptoms. Evaluation of end points is
      at 16 weeks. The trial is set up with six study visits. Patient recruitment, eligibility
      screening and retrieval of informed consent will be performed at OUS before inclusion. At
      visit 1, and 6 patients will undergo clinical examination, PFTs, at all visits clinical
      examination and sampling of biological material.
    
  